AstraZeneca PLCAZN

NYSEHealthcarePharmaceuticals$189.90-1.35%

A global biopharmaceutical company focused on the development and commercialization of prescription medicines, with core franchises in oncology, cardiovascular, renal and metabolism, respiratory, immunology, and rare diseases. Revenue is driven by a portfolio of blockbuster therapies and an extensive late-stage pipeline, making clinical trial data, regulatory approvals, and patent expirations key catalysts for investors. With a significant international footprint and exposure to pricing and reimbursement trends, it is closely watched for pipeline execution and capital allocation decisions.

Market Cap: $294.4B52W Range: $122.48 – $212.71

Congressional Interest in AstraZeneca PLC (AZN)

8 members of Congress have disclosed 23 trades in AstraZeneca PLC (AZN), a Healthcare company. The buy/sell breakdown shows 13 purchases versus 10 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.